LOS ANGELES, March 19, 2025 (GLOBE NEWSWIRE) — Comprehensive Urology launches its new observational study, TEM-C for Chronic Urinary Tract Infections (UTIs) for women under the expert guidance of Principal Investigator and Urologist, Kia Michel, MD.

According to the American Society of Microbiology, about 400 million people suffer from UTI’s worldwide, with 150 million UTI infections happening in the US alone. Chronic UTIs are when the same individual gets recurrent UTIs, usually multiple times per year. Untreated UTIs can progress into more complicated bladder infections and kidney infections that permanently damage the urinary tract.

Top Urologist Dr. Kia Michel emphasized the importance of the TEM-C study: “We are excited to launch TEM-C, which could potentially pave the way for new insights and treatment strategies for chronic UTI sufferers. We want to see if a comprehensive approach using numerous therapies at the same time can reduce the recurrence of these debilitating infections.”

TEM–C Stands for (Thermiva-Estrogen-Methenamine-Colloidal Vit C in oral suspension).

• ThermiVa: This is a small device that uses radiofrequency waves to gently heat the vaginal tissues. Previous studies have found that ThermiVa stimulates collagen production, which strengthens and tightens the vaginal walls and encourages new blood vessel growth. The improved vaginal blood flow and urethral support helps reduce the likelihood of getting urinary tract infections in women.

• Estrogen Therapy: In previous studies, estrogen, in women who are deficient has been found to maintain a healthy vulva and urethra that is more resilient to infections.

• Methenamine: An FDA approved anti-infection medication that is used to prevent recurrent UTIs.

• Colloidal Vit C: Vitamin C in oral suspension helps maintain the health of blood vessels and the immune system. It can also help wounds heal faster and protect cells as an antioxidant.

One of the innovative aspects of the TEM-C study is the combination of therapies with Methenamine hippurate, a treatment option that has shown promise in preventing recurrent UTIs. Methenamine works by creating an environment in the bladder that is hostile to bacterial growth, thus reducing the frequency of infections. A multicenter, randomized trial in the UK published in the BMJ highlighted that Methenamine hippurate is effective in preventing recurrent UTIs and offers a viable alternative to continuous antibiotic prophylaxis, which can increase antibiotic resistance.

Dr. Michel explains that TEM-C is studying the combination of “restoring the urinary tract to a healthy state through optimization of the vaginal and urethral tissue with Thermiva, Estrogen Therapy and Colloidal Vitamin C while also suppressing the ability of bacteria to gain access to the bladder with Methenamine. With this comprehensive approach, we aim to reduce the recurrence of UTIs in women.”